TrialBlood advances2019

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Steven E Coutre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.